Reading the tape
NYSE: RCUS
Arcus Biosciences, Inc.
Healthcare · Biotechnology
Market Cap
$2.55B
52w High
$28.72
52w Low
$7.06
P/E
-7.71
Volume
667.37K
Outstanding Shares
100.67M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 183.89%Revenue (TTM): -4.26%FCF (TTM): -175%P/S: 39th pct
What changed
The stock rose 183.89% over the last year. Revenue declined 4.26% over the trailing twelve months. Operating margin moved from -127.91% to -156.28%. Free cash flow declined 175% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -156.28%. A decisive move in revenue — currently down 4.26% — would be the clearest signal to resolve the ambiguity.
Company profile
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
CEOTerry J. Rosen
SectorHealthcare
IndustryBiotechnology
Employees627
IPO dateMar 15, 2018
Valuation
Forward P/E—
EV/EBITDA-7.27
Enterprise value$2.44B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth26.92%
Gross margin97.98%▼4.05%vs FY2024
Operating margin-156.28%▼22.18%vs FY2024
ROE-55.94%▲4.13%vs FY2024
Analyst consensus
RatingBuy
Target price$30.00▲18.46%
15
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$0.92 · Revenue est $29.48M
View